PALVELLA THERAPEUTICS Business Summary

Palvella Therapeutics, Inc. (PVLA) is a late-stage clinical biopharmaceutical company that generates value through the development and planned commercialization of novel therapies for serious, rare genetic skin diseases. The company’s business model centers on its proprietary QTORIN™ platform, a localized delivery technology designed to provide high-potency treatment to pathogenic skin tissue while minimizing systemic exposure. Its primary business segments are categorized by therapeutic indications, including microcystic lymphatic malformations (mLM), cutaneous venous malformations (cVM), and disseminated superficial actinic porokeratosis (DSAP). Palvella operates in a specialized orphan drug market, competing with firms such as BridgeBio, Centessa Pharmaceuticals, and Erasca; it distinguishes itself by targeting niche dermatological and vascular malformations that currently lack any FDA-approved therapies, positioning the company as a potential first-to-market leader in these high-unmet-need categories. The company is led by Founder and CEO Wes Kaupinen, a rare disease veteran with a pedigree including leadership roles at Insmed and investment experience at Apax Partners and Quaker Partners. The executive team includes CFO Matthew E. Korenberg, formerly of Ligand Pharmaceuticals and Goldman Sachs; Chief Scientific Officer Jeff Martini, Ph.D.; and Chief Commercial Officer Ashley Kline, who brings experience from Genentech and Bain & Company. Palvella’s strategic direction is supported by a board chaired by George Jenkins and featuring Todd Davis, with significant backing from premier healthcare investors including BVF Partners, Frazier Life Sciences, Samsara BioCapital, and Blue Owl Healthcare Opportunities. This leadership group recently oversaw the company’s transition to the public markets via a December 2024 merger, securing the capital necessary to advance its lead candidate, QTORIN™ rapamycin, through pivotal Phase 3 readouts in 2026.